• Fulfilling


    With the Science of Enzymes

  • Fulfilling


    In the Treatment of 

    Gastrointestinal and Rare Diseases

  • Helping


    Fulfill Their Potential

News & Media

Alcresta Therapeutics, Inc. Presented Results at the North American Cystic Fibrosis Conference from the ASSURE Study: An Evaluation of the Long-Term Use of RELiZORB®

Nov 06, 2017

Four additional studies with RELiZORB were presented by investigators at leading cystic fibrosis centers

Alcresta Therapeutics Receives New Innovative Technology Contract from Vizient, Inc. For RELiZORB® (iMMOBILIZED LIPASE) Cartridge

Sep 20, 2017

WARREN, N.J.--(BUSINESS WIRE)--Alcresta Therapeutics, Inc. announced RELiZORB has received an Innovative Technology contract from Vizient, Inc. the largest member-driven health care performance improvement company in the country. The awarded contract, effective Sept. 1, 2017, was based on a recommendation of RELiZORB by hospital members who serve on one of Vizient’s member-led councils.

Alcresta Therapeutics Announces Positive Results, RELiZORB® Increased Fat Absorption in Both Adult and Pediatric Patients with Cystic Fibrosis Receiving Enteral Nutrition

Jul 31, 2017

RELiZORB significantly increased plasma levels of omega-3 fatty acids and patients reported a decrease in the frequency of gastrointestinal symptoms in a Pivotal Clinical Trial